Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 7
Submit an article Journal homepage
202
Views
29
CrossRef citations to date
0
Altmetric
Review

Anti-TNF-α therapy in ankylosing spondylitis

Daniel Wendling University Teaching Hospital Minjoz, Department of Rheumatology, Boulevard Fleming, F-25030 Besançon, France. [email protected]
&
Eric Toussirot University Teaching Hospital Minjoz, Department of Rheumatology, Boulevard Fleming, F-25030 Besançon, France
Pages 1497-1507 | Published online: 25 Feb 2005

Bibliography

  • SIEPER J, BRAUN J, RUDWALEIT M, BOONEN A, ZINK A: Ankylosing spondylitis: an overview. Ann. Rheum. Dis. (2002) 61(Suppi. 3):i118–i1118.
  • VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum. (1984) 27(4):361–368.
  • BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA B 27-positive and -negative blood donors. Arthritic Rheum. (1998) 41(1):58–67.
  • GRAN JT, HUSBY G, HORDVIK M: Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann. Rheum. Dis. (1985) 44(6):359–367.
  • GUILLEMIN F, SARAUX A, GUGGENBUHL P et al.: Prevalence de la polyarthrite rhematoide et des spondylarthropathies en France en 2001. Rev Rhum. (2002) 69(10-11):1014.
  • BOONEN A, CHORUS A, MIEDEMA H, VAN DER HEIJDE D, VAN DER TAMPLE H, VAN DER LINDEN SJ: Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann. Rheum. Dis. (2001) 60(4):353–358.
  • KHAN MA, KHAN MK, KUSHNER I: Survival among patients with ankylosing spondylitis: a life-table analysis. Rheumatul (1981) 8(1):86–90.
  • AMOR B, SANTOS RS, NAHAL R, LISTRAT V, DOUGADOS M: Predictive factors for the long term outcome of spondylarthropathies. I Rheumatul (1994) 21(10):1884–1887.
  • BOONEN A: Socioeconomic consequences of ankylosing spondylitis. Clin. Exp. Rheumatul (2002) 20\(Suppl. 28):523–526.
  • VAN TUBERGEN A, LANDEWE R, VAN DER HEIJDE D et al.: Combined spa-exercise is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritic Rheum. (2001) 45(5):430–438.
  • WARD MM: Predictors of the progression of functional disability in patients with ankylosing spondylitis. Rheumatul (2002) 16(4):691–705.
  • TOUSSIROT E, WENDLING D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs (1998) 56(2):225–240.
  • MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA et al.: A six-month randomized, controlled, double-blind, dose response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. (2002) 46(3):766–773.
  • VAN DER HEIJDE D, BELLAMY N, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in ankylosing spondylitis working group. Rheumatul (1997) 24(12):2225–2229.
  • ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. (2001) 44(8):1876–1886.
  • ONIANKITAN O, RANAIVO N, CARTON L, CHEVALIER X, CLAUDEPIERRE P: Efficacité des traitements conventionnels dans les spondylarthropathies: le point de vue du patient. Rev Rhum. (2002) 69(10-11):1025–1026.
  • BARKHAM N, KONG KO, FRASER A, TENNANT A, EMERY P: The unmet need for effective therapy in ankylosing spondylitis. Arthritis Rheum. (2003) 48(9 Suppl.):S175.
  • WANDERS A, VAN DER HEIJDE D, LANDEWE R et al.: Inhibition of radiographic progression in ankylosing spondylitis by continuous use of NSAIDs. Arthritis Rheum. (2003) 48(9 Suppl.):S233.
  • GRATAGOSJ, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNF-a, IFN-y) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. Rheumatul. (1994) 33(10):927–931.
  • BRAUN J, BOLLOW M, NEURE L et al: Use of immunohistologic and in situ hybridisation techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38(4):499–505.
  • •A demonstration of intra-articular production of TNF-a in AS.
  • VAN DEN BOSCH F, KRUITHOF E, DE VOS M, DE KEYSER F, MIELANTS H: Crohn's disease associated with spondyloarthropathy: effect of TNF-a blockade with Infliximab on articular symptoms. Lancet (2000) 356(9244):1821–1822.
  • BRANDT J, HAIBEL H, CORNELY D, GOLDER W et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody Infliximab. Arthritis Rheum. (2000) 43(6):1346–1352.
  • BRANDT J, HAIBEL H, SIEPER J, REDDIG J, BRAUN J: Infliximab treatment of severe ankylosing spondylitis: one year follow-up. Arthritis Rheum. (2001) 44(12):2936–2937.
  • STONE M, SALONEN D, LAX M, PAYNE U, LAPP V, INMAN R: Clinical and imaging correlates of response to treatment with Infliximab in patients with ankylosing spondylitis. Rheumatul (2001) 28(7):1605–1614.
  • MAKSYMOWYCH WP, JHANGRI GS, LAMBERT RG et al.: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of afficacy and safety. J. Rheumatul (2002) 29(5):959–965.
  • BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of Infliximab in refractory ankylosing spondylitis: results of a 6-month open label study. Rheumatology (2002) 41(11):1280–1285.
  • COLLANTES-ESTEVEZ E, MUNOZ-VILLANUEVA MC, CANETE-CRESPILLO JD et al.: Infliximab in refractory spondyloarthropathies: a multicentre
  • week open study. Ann. Rheum. Dis. (2003) 62(12):1239–1240.
  • TEMEKONIDIS TI, ALAMANOS Y, NIKAS SN et al.: Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann. Rheum. Dis. (2003) 62(12):1218–1220.
  • VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor a ( Infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59(6):428–433.
  • KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: Repeated infusions of Infliximab, a chimeric anti-TNFa monoclonal antibody, in patients with active spondyloarthropathy: one year follow-up. Ann. Rheum. Dis. (2002) 61(3):207–212.
  • BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with Infliximab: a randomised controlled multicentre trial. Lancet (2002) 359(9313):1187–1193.
  • ••The first controlled study in ASwith infliximab.
  • VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (Infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. (2002) 46(3):755–765.
  • ••A controlled study with infliximab in SpA.
  • MARZO-ORTEGA H, MACGONAGLE D, O'CONNOR P, EMERY P: Efficacy of Etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy. Arthritis Rheum. (2001) 44(9):2112–2117.
  • GORMAN J, SACK K, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumof necrosis factor (alpha). N Engl. J. Med. (2002) 346(18):385–390.
  • ••The first controlled study withetanercept in AS.
  • BRANDT J, KARIOUZOV A, LISTING J et al.: Six months results of a german double-blind placebo controlled, Phase III clinical trial of Etanercept in active ankylosing spondylitis. Arthritis Rheum. (2003) 48(6):1667–1675.
  • ••Additional proof of the efficacy ofetanercept in AS.
  • DAVIS JC, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitis. A randomized controlled trial. Arthritis Rheum. (2003) 48(1 1):3230–3236.
  • ••The largest controlled study in this field.
  • BRANDT J, HAIBEL H, REDDIG J, SIEPERJ, BRAUN J: Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-a monoclonal antibody Infliximab. Rheumatul (2002) 29(1):118–122.
  • MEASE PJ, GOFFE BS, METZ J, VAN DER STOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356(9227):385–390.
  • SALVARANI C, CANTINI F, OLIVIERI I et al.: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. (2003) 49(4):541–545.
  • ANTONI C, KAVANAUGH A, KIRKHAM B et al.: The one year results of the Infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. (2003) 48\(Suppl. 9):S265.
  • KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: Repeated infusions of Infliximab, a chimeric anti-TNFa monoclonal antibody, in patients with active spondyloarthropathy: one year follow-up. Ann. Rheum. Dis. (2002) 61(3):207–212.
  • BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with Infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann. Rheum. Dis. (2003) 62 (9):829–834.
  • BRAUN J, BRANDT J, LISTING J et al: Long-term efficacy and safety of Infliximab in the treatment of ankylosing spondylitis. An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. (2003) 48(8):2224–2233.
  • BOEGER CA, WITTWER H, SCHATTENKIRCHNER M, KELLNER H, KELLNER W: Treatment of ankylosing spondylitis with infliximab. Ann. Rheum. Dis. (2001) 60(12):1159–1160.
  • BRAUN J, BARALIAKOS X, GOLDER W et al.: Magnetic resonance examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab. Evaluation of a new scoring system. Arthritis Rheum. (2003) 48(4):1126–1136.
  • •Demonstration of MRI efficacy, and proposal of a new scoring system.
  • HADI A, HICKLINGP, BROWN M, AL-NAHHAS A: Scintigraphic evidence of effect of Infliximab on disease activity in ankylosing spondylitis. Rheumatology (2002) 41(1):114–116.
  • D'AGOSTINO MA, BREBAN M, SAID-NAHAL R, DOUGADOS M: Refractory inflammatory heel pain in spondylarthropathy: a significant response to Infliximab documented by ultrasound. Arthritis Rheum. (2002) 46(3):840–842.
  • ALLALI F, BREBAN M, PORCHER R, MAILLEFERT JF, DOUGADOS M, ROUX C: Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor a. Ann. Rheum. Dis. (2003) 62(4):347–349.
  • MARZO-ORTEGA H, MCGONAGLE D, HAUGEBERG G, GREEN MJ, STEWART SP, EMERY P: Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann. Rheum. Dis. (2003) 62(10):1020–1021.
  • BOKAREWA M, TARKOWSKI A: local infusion of Infliximab for the treatment of acute joint inflammation. Ann. Rheum. Dis. (2003) 62(8):783–784.
  • KELLER C, WEBB A, DAVIS J: Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann. Rheum. Dis. (2003) 62(12):1128–1132.
  • •A review of the immunological modifications induced by anti-TNF therapy in SpA.
  • BAETEN D, NAN DAMME N, VAN DEN BOSCH F et al: Impaired Thl cytokine production in spondyloarthropathy is restored by anti-TNFa. Ann. Rheum. Dis. (2001) 60(8):750–755.
  • ZOU J, RUDWALEIT M, BRANDT J, THIEL A, BRAUN J, SIEPER J: Down-regulation of the non specific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with Infliximab. Arthritis Rheum. (2003) 48(3):780–790.
  • ZOU J, RUDWALEIT M, BRANDT J, THIEL A, BRAUN J, SIEPER J: Up regulation of the production of tumour necrosis factor a and interferon 7 by T cells in ankylosing spondylitis during treatment with etanercept. Ann. Rheum. Dis. (2003) 62(6):561–564.
  • BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Immunomodulatory effects of anti tumor necrosis factor a therapy on synovium in spondylarthropathy. Arthritis Rheum. (2001) 44(1):186–195.
  • WENDLING D: Anti-TNFa therapy in spondyloarthropathy: deciding who to treat. Joint Bone Spine (2003) 70(6):401–403.
  • BRAUN J, PHAM T, SIEPERJ, DAVIS J, VAN DER LINDEN S, VAN DER HEIJDE D: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2003) 62(9):817–824.
  • ••Guidelines for the current use ofanti-TNF in AS.
  • SALMON D, for the GTI and AFSSAPS.Groupe Tuberculose et infliximab. Agence Francaise de Securite Sanitaire de Produits de Sante: Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine (2002) 69(3):170–172.
  • MAKSYMOWYCH WP, INMAN RD, GLADMAN D et al.: Canadian rheumatology association consensus on the use of anti-tumour necrosis factor a directed therapies in the treatment of spondyloarthritis. J Rheumatol (2003) 30(6):1356–1363.
  • STONE MA, PAYNE U, PACHECO-TENA C, INMAN R: Cytokine correlates of clinical response patterns to Infliximab treatment of ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(1):84–87.
  • BRAUN J, VAN DER HEIJDE D: Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin. Investig. Drugs (2003) 12(7):1097–1109.
  • RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to TNF-a blockers in ankylosing spondylitis? Ann. Rheum. Dis. (2004) 63(6):665–670.
  • TOUSSIROT E, WENDLING D: The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother: (2004) 5(3):581–594.
  • VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab when etanercept has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann. Rheum. Dis. (2003) 62(12):1195–1198.

Websites

  • http://www.nice.org.uk National Institute For Clinical Excellence (NICE): guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. March (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.